IL17A and myeloid sarcoma: The expression of miR-155 is increased in the serum of MS patients, especially during the relapse period; miR-155 enhances the differentiation of Th17 and Th1 cells by increasing the cytokine production of both IL-17A and IFN-γ, which sustain the inflammation response and aggravate clinical signs of the EAE model (Zhang et al., 2014).